Annual Meeting of the International Society of Cancer Metabolism (ISCaM): Metabolic Adaptations and Targets in Cancer.

cancer imaging cancer metabolism cancer therapy proton dynamics tumor microenvironment

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2019
Historique:
received: 14 09 2019
accepted: 14 11 2019
entrez: 19 12 2019
pubmed: 19 12 2019
medline: 19 12 2019
Statut: epublish

Résumé

The metabolism of cancer cells differs from that of their normal counterparts in a spectrum of attributes, including imbalances in diverse metabolic arms and pathways, metabolic plasticity and extent of adaptive responses, levels, and activities of metabolic enzymes and their upstream regulators and abnormal fluxes of metabolic intermediates and products. These attributes endow cancer cells with the ability to survive stressors of the tumor microenvironment and enable them to landscape and exploit the host terrain, thereby facilitating cancer progression and therapy resistance. Understanding the molecular and physiological principles of cancer metabolism is one of the key prerequisites for the development of better anticancer treatments. Therefore, various aspects of cancer metabolism were addressed at the 5th annual meeting of the International Society of Cancer Metabolism (ISCaM) in Bratislava, Slovakia, on October 17-20, 2018. The meeting presentations and discussions were traditionally focused on mechanistic, translational, and clinical characteristics of metabolism and pH control in cancer, at the level of molecular pathways, cells, tissues, and organisms. In order to reflect major healthcare challenges of the current era, ISCaM has extended its scope to metabolic disorders contributing to cancer, as well as to opportunities for their prevention, intervention, and therapeutic targeting.

Identifiants

pubmed: 31850217
doi: 10.3389/fonc.2019.01332
pmc: PMC6892776
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1332

Informations de copyright

Copyright © 2019 Avnet, Baldini, Brisson, Pedersen, Porporato, Sonveaux, Szabadkai and Pastorekova.

Références

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2715-26
pubmed: 25449995
Front Pharmacol. 2017 Jul 04;8:411
pubmed: 28725193
Front Oncol. 2018 Oct 03;8:329
pubmed: 30338239

Auteurs

Sofia Avnet (S)

Orthopaedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Nicola Baldini (N)

Orthopaedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Lucie Brisson (L)

INSERM UMR1069, Nutrition, Croissance et Cancer, University of Tours, Tours, France.

Stine Falsig Pedersen (SF)

Department of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.

Paolo E Porporato (PE)

Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Turin, Italy.

Pierre Sonveaux (P)

Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.

Gyorgy Szabadkai (G)

Department of Biomedical Sciences, University of Padua, Padua, Italy.
Department of Cell and Developmental Biology, Consortium for Mitochondrial Research, University College London, London, United Kingdom.
The Francis Crick Institute, London, United Kingdom.

Silvia Pastorekova (S)

Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.

Classifications MeSH